Latest From Tolerx Inc.
The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.
The British pharma is expanding its portfolio in rheumatoid arthritis through a mid-stage tie-up with German biotech MorphoSys. GSK will take over all development of the antibody and could pay milestones up to €425 million.
Andromeda Biotech has released top-line results for its lead product, DiaPep277, that suggest it could prove an effective immunotherapeutic product for patients with newly diagnosed type 1 diabetes.
Autoimmune treatments in type 1 diabetes hold forth the promise of preserving the body’s own insulin production. However, three late-stage candidates – teplizumab, otelixizumab, and Diamyd – have failed to show that they can prevent beta-cell destruction in type 1 patients.
- Large Molecule
- Therapeutic Areas
- TolerRx Inc.
- North America
- Parent & Subsidiaries
- Tolerx Inc.
- Senior Management
Douglas J Ringler, Pres. & CEO
Antonin (Tony) de Fougerolles, PhD, CSO
- Contact Info
Phone: (617) 354-8100
300 Technology Sq.
Cambridge, MA 02139
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.